09:32 AM EDT, 10/22/2024 (MT Newswires) -- Grifols ( GRFS ) said Tuesday it has launched a partnership with the Biomedical Advanced Research and Development Authority, or BARDA, to assess investigational ocular surface immunoglobulin eye drops to treat damage from exposure to sulfur mustard, a chemical warfare agent.

The company said BARDA is part of the US Department of Health and Human Services' Administration for Strategic Preparedness and Response.

Grifols ( GRFS ) said that if the preclinical assessment is successful, the US Food and Drug Administration may license the treatment to address the long-term effects of sulfur mustard eye injury.

The company said it will develop a treatment for sulfur mustard eye exposure by repurposing an investigational treatment that is in development for dry eye disease.

Price: 8.69, Change: +0.12, Percent Change: +1.40